Guardant Health, Inc. (GH) Balance Sheet

The balance sheet is weakening as accumulated deficits deepen, with retained earnings falling from -$2.3B to -$3.2B over the period. This trend suggests the company is prioritizing growth over balance sheet strength, consistent with the 44% revenue surge but also with escalating cash burn. Investors should monitor whether the pace of equity erosion slows as the company scales.

The D/E ratio is not reported due to negative equity, but debt-to-assets climbed from 0.76 to 0.89, suggesting increased reliance on debt financing. The cash position provides a temporary cushion, but the rising debt and negative equity imply that the company may need to refinance or raise equity, especially if cash burn persists. The $1.7B debt likely includes convertible notes, which could dilute shareholders if converted.

The 23x increase in goodwill suggests a significant acquisition, likely related to the Shield program or technology, which may carry impairment risk if expected synergies fail to materialize. PPE growth has been modest, indicating a relatively asset-light model, but the rising intangibles warrant monitoring for potential write-downs.

The negative equity is a red flag, but it is common for high-growth biotech firms. Retained earnings deficits grew by $900M over the period, while SBC has been a major non-cash charge, as noted in the cash flow analysis. This suggests that dilution is a key mechanism for funding operations, which could pressure existing shareholders.

Despite a strong current ratio, the trend is downward, and the cash runway is limited given the quarterly cash burn of around $70M. The $1.1B cash provides roughly 15 quarters of runway at current burn rates, but this assumes no acceleration in spending. The company's ability to access capital markets may be constrained by its negative equity and weak profitability.